The DESTINY-Breast06 Phase III trial yielded encouraging results, demonstrating the effectiveness of Enhertu (trastuzumab deruxtecan) in improving progression-free survival (PFS) significantly and meaningfully compared to standard chemotherapy. This positive outcome…
AbbVie Initiates Construction of State-of-the-Art Research Hub, “LUnA,” in Germany with €150 Million Investment AbbVie has commenced the construction of its new central research building, dubbed “LUnA” (LUdwighafens neue Arbeitswelt),…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has revealed findings from its Phase 3 trial, STRIDE-10, assessing V116, the company’s advanced 21-valent pneumococcal…
Recognizing the Stealthy Signs of Bladder Cancer Identifying bladder cancer in its early stages can be challenging, as its symptoms often mimic those of benign conditions like urinary tract infections…
Eli Lilly and Company (NYSE: LLY) unveiled its financial performance for the first quarter of 2024 today. David A. Ricks, Lilly’s chair and CEO, commented on the company’s robust year-over-year…
Alentis Therapeutics, a cutting-edge biotech firm dedicated to combatting organ fibrosis and Claudin-1 positive tumors, has just announced the appointment of Dr. Alberto Toso as its Chief Scientific Officer, effective…
In today’s fast-paced world, the essence of healthcare often gets lost in the shuffle. Johnson & Johnson, however, is on a mission to redefine the meaning behind two fundamental words:…
Eli Lilly and Company (NYSE: LLY) has received notification of an unsolicited “mini-tender” offer from Tutanota LLC (“Tutanota”), proposing to acquire up to 62,500 shares of Lilly common stock, which…
Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a pioneering molecular diagnostics firm, proudly introduce the Bio-Marker Pathfinder (BMP), a groundbreaking ocular biomarker kit designed for point-of-care application. Novomol-Dx specializes in commercializing…
Shionogi & Co., Ltd. (Headquartered in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.; hereafter referred to as “Shionogi”) has announced revisions to its dividend forecasts for the fiscal year ending March…
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a prominent global oncology firm, has unveiled its 2023 Responsible Business & Sustainability Report, spotlighting the company’s strategic direction, progress towards existing…
Bayer Group’s divisions demonstrated resilience and strength in several core areas, surpassing industry peers, according to CEO Bill Anderson during the virtual Annual Stockholders’ Meeting. Anderson praised the progress in…